dovramilast

Dovramilast (CC-11050, AMG 634) is an oral small molecule phosphodiesterase type 4 (PDE4) inhibitor. Originally developed by Celgene and later acquired by Amgen as part of the Otezla (apremilast) divestiture, it is a derivative of apremilast designed to modulate inflammatory responses. The drug works by inhibiting the PDE4 enzyme, which increases intracellular levels of cyclic adenosine monophosphate (cAMP), thereby suppressing the production of pro-inflammatory cytokines such as TNF-alpha. In 2020, Amgen licensed the compound to the non-profit Medicines Development for Global Health (MDGH) for the development of treatments for neglected tropical diseases. It is currently being investigated in Phase 2 clinical trials for tuberculosis and erythema nodosum leprosum (ENL), a severe inflammatory complication of leprosy, and has previously been studied for cutaneous lupus erythematosus and HIV-associated inflammation.

Other names

dovramilast